CLDN3 and cholangiocarcinoma: In conclusion, our experiments demonstrated that PPM1G can inhibit EMT in CCA by catalyzing the dephosphorylation of TET1 and destabilizing it, thereby weakening the targeted demethylation of the CLDN3 promoter region by TET1.